دورية أكاديمية
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
| العنوان: | Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis. |
|---|---|
| المؤلفون: | Becherini, Carlotta, Visani, Luca, Caini, Saverio, Bhattacharya, Indrani S, Kirby, Anna M, Nader Marta, Gustavo, Morgan, Gilberto, Salvestrini, Viola, Coles, Charlotte E, Cortes, Javier, Curigliano, Giuseppe, de Azambuja, Evandro, Harbeck, Nadia, Isacke, Clare M, Kaidar-Person, Orit, Marangoni, Elisabetta, Offersen, Birgitte, Rugo, Hope S, Morandi, Andrea, Lambertini, Matteo, Poortmans, Philip, Livi, Lorenzo, Meattini, Icro |
| بيانات النشر: | Elsevier BV Department of Oncology //dx.doi.org/10.1016/j.ctrv.2023.102586 Cancer Treat Rev |
| سنة النشر: | 2023 |
| المجموعة: | Apollo - University of Cambridge Repository |
| مصطلحات موضوعية: | Breast cancer, CDK4/6 inhibitors, Meta-analysis, Radiotherapy, Systematic review, Toxicity, Humans, Female, Radiosurgery, Breast Neoplasms, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase 4, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 6, Antineoplastic Combined Chemotherapy Protocols |
| الوصف: | The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have become the standard of care for hormone receptor-positive (HR + ) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, improving survival outcomes compared to endocrine therapy alone. Abemaciclib and ribociclib, in combination with endocrine therapy, have demonstrated significant benefits in invasive disease-free survival for high-risk HR+/HER2- early breast cancer patients. Each CDK4/6i-palbociclib, ribociclib, and abemaciclib-exhibits distinct toxicity profiles. Radiation therapy (RT) can be delivered with a palliative or ablative intent, particularly using stereotactic body radiation therapy for oligometastatic or oligoprogressive disease. However, pivotal randomized trials lack information on concomitant CDK4/6i and RT, and existing preclinical and clinical data on the potential combined toxicities are limited and conflicting. As part of a broader effort to establish international consensus recommendations for integrating RT and targeted agents in breast cancer treatment, we conducted a systematic review and meta-analysis to evaluate the safety profile of combining CDK4/6i with palliative and ablative RT in both metastatic and early breast cancer settings. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://www.repository.cam.ac.uk/handle/1810/357000Test |
| الإتاحة: | https://www.repository.cam.ac.uk/handle/1810/357000Test |
| حقوق: | Attribution 4.0 International ; https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.8E0E0EA0 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |